BACKGROUND: Many clinical trials testing Ginkgo biloba extract EGb 761 in patients with mild forms of cognitive impairment were conducted before widely accepted terms and diagnostic criteria for such conditions were available. This makes it difficult to compare any results from earlier and more recent trials. The objective of this systematic review was to provide a descriptive overview of clinical trials of EGb 761 in patients who met the diagnostic criteria for mild neurocognitive disorder (mild NCD) according to the Diagnostic and Statistical Manual of Mental Disorders, fifth edition (DSM-5). METHODS: MEDLINE, PubMed and EMBASE were searched for randomized, placebo-controlled double-blind trials of EGb 761 in mild impairment of cognitive functioning. All trials involving patients who met retrospectively applied diagnostic criteria for mild NCD were included. Trials of primary prevention of dementia and trials of combinations of medical treatments were excluded. RESULTS: Among 298 records found in databases and 76 further records related to EGb 761 in references of systematic reviews, 9 reports on clinical trials involving 946 patients met the pre-specified criteria for inclusion. Beneficial effects of EGb 761 were seen in neuropsychological tests (8 of 9 studies), scales for neuropsychiatric symptoms (3 of 3 studies), geriatric rating scales (1 of 2 studies) and global ratings of change (1 of 1 study). Significant effects were found in several domains of cognition (memory, speed of processing, attention and executive functioning). Among the neuropsychiatric symptoms, depression (2 of 3 studies) and anxiety (1 of 1 study) were significantly improved. No differences between EGb 761 treatment and placebo were seen with regard to the rates of adverse events. DISCUSSION: The included studies demonstrate treatment benefits of Ginkgo biloba extract EGb 761, mainly on cognitive deficits and neuropsychiatric symptoms, in patients with mild NCD. The drug was safe and well tolerated.

Department of Neurology Klinikum Bremen Ost Bremen Germany

Memory Clinic Department of Neurology Charles University 2nd Faculty of Medicine and Motol University Hospital Prague Czech Republic

Research and Development Dr Willmar Schwabe GmbH and Co KG Karlsruhe Germany

Zobrazit více v PubMed

American Psychiatric Association. Neurocognitive Disorders. Diagnostic and Statistical Manual of Mental Disorders (DSM-3). 3rd ed. American Psychiatric Association; 1980.

McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer’s disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer’s Disease. Neurology. 1984;34(7):939–944. doi:10.1212/wnl.34.7.939 PubMed DOI

Kral VA. Senescent forgetfulness: benign and malignant. Can Med Assoc J. 1962;86(6):257–260. PubMed PMC

Crook T, Larrabee GJ. Age-associated memory impairment: diagnostic criteria and treatment strategies. Psychopharmacol Bull. 1988;24(4):509–514. PubMed

Levy R. Aging-associated cognitive decline. Int Psychogeriatr. 1994;6(1):63–68. doi:10.1017/s1041610294001626 PubMed DOI

Ebly EM, Hogan DB, Parhad IM. Cognitive impairment in the nondemented elderly. Results from the Canadian Study of Health and Aging. Arch Neurol. 1995;52(6):612–619. doi:10.1001/archneur.1995.00540300086018 PubMed DOI

Zaudig M. A new systematic method of measurement and diagnosis of “Mild Cognitive Impairment” and dementia according to ICD-10 and DSM-III-R criteria. Int Psychogeriatr. 1992;4(Suppl. 2):203–219. doi:10.1017/S1041610292001273 PubMed DOI

Petersen RC, Smith GE, Waring SC, Ivnik RJ, Kokmen E, Tangelos EG. Aging, memory, and mild cognitive impairment. Int Psychogeriatr. 1997;9(Suppl 1):65–69. doi:10.1017/s1041610297004717 PubMed DOI

Petersen RC, Smith GE, Waring SC, Ivnik RJ, Tangalos EG, Kokmen E. Mild cognitive impairment: clinical characterization and outcome. Arch Neurol. 1999;56(3):303–308. doi:10.1001/archneur.56.3.303 PubMed DOI

Petersen RC. Mild cognitive impairment as a diagnostic entity. J Intern Med. 2004;256(3):183–194. doi:10.1111/j.1365-2796.2004.01388.x PubMed DOI

Winblad B, Palmer K, Kivipelto M, et al. Mild cognitive impairment--beyond controversies, towards a consensus: report of the International Working Group on Mild Cognitive Impairment. J Intern Med. 2004;256(3):240–246. doi:10.1111/j.1365-2796.2004.01380.x PubMed DOI

Albert MS, DeKosky ST, Dickson D, et al. The diagnosis of mild cognitive impairment due to Alzheimer’s disease: recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement. 2011;7(3):270–279. doi:10.1016/j.jalz.2011.03.008 PubMed DOI PMC

Dubois B, Feldman HH, Jacova C, et al. Research criteria for the diagnosis of Alzheimer’s disease: revising the NINCDS–ADRDA criteria. Lancet Neurol. 2007;6(8):734–746. doi:10.1016/s1474-4422(07)70178-3 PubMed DOI

Dubois B, Feldman HH, Jacova C, et al. Advancing research diagnostic criteria for Alzheimer’s disease: the IWG-2 criteria. Lancet Neurol. 2014;13(6):614–629. doi:10.1016/s1474-4422(14)70090-0 PubMed DOI

American Psychiatric Association. Diagnostic and Statistical Manual of mental disorders (DSM-5). 5th ed. Neurocognitive Disorders. American Psychiatric Association; 2013.

Matsunaga S, Fujishiro H, Takechi H. Efficacy and safety of cholinesterase inhibitors for mild cognitive impairment: a systematic review and meta-analysis. J Alzheimers Dis. 2019;71(2):513–523. doi:10.3233/JAD-190546 PubMed DOI

Petersen RC, Thomas RG, Grundman M, et al. Vitamin E and donepezil for the treatment of mild cognitive impairment. N Engl J Med. 2005;352(23):2379–2388. doi:10.1056/NEJMoa050151 PubMed DOI

Jeremic D, Jiménez-Díaz L, Navarro-López JD. Past, present and future of therapeutic strategies against amyloid-β peptides in Alzheimer’s disease: a systematic review. Ageing Res Rev. 2021;72:101496. doi:10.1016/j.arr.2021.101496 PubMed DOI

Haddad HW, Malone GW, Comardelle NJ, Degueure AE, Kaye AM, Kaye AD. Aducanumab, a novel anti-amyloid monoclonal antibody, for the treatment of Alzheimer’s disease: a comprehensive review. Health Psychol Res. 2022;10(1):31925. doi:10.52965/001c.31925 PubMed DOI PMC

Kapasi A, DeCarli C, Schneider JA. Impact of multiple pathologies on the threshold for clinically overt dementia. Acta Neuropathol. 2017;134(2):171–186. doi:10.1007/s00401-017-1717-7 PubMed DOI PMC

Rabin JS, Schultz AP, Hedden T, et al. Interactive associations of vascular risk and beta-amyloid burden with cognitive decline in clinically normal elderly individuals: findings from the Harvard aging brain study. JAMA Neurol. 2018;75(9):1124–1131. doi:10.1001/jamaneurol.2018.1123 PubMed DOI PMC

Erdincler DS, Karakoc Y, Toplan S, et al. The effect of Ginkgo biloba glycoside on the blood viscosity and erythrocyte deformability. Clin Hemorheol. 1996;16(3):271–276.

Lang F, Hoerr R, Noeldner M, Koch E. Ginkgo biloba extract EGb 761: from an ancient asian plant to a modern european herbal medicinal product. In: Wagner H, Ulrich-Merzenich G, editors. Evidence and Rational Based Research on Chinese Drugs. Springer Vienna; 2013:431–470.

Huang SY, Jeng C, Kao SC, Yu JJ, Liu DZ. Improved haemorrheological properties by Ginkgo biloba extract (Egb 761) in type 2 diabetes mellitus complicated with retinopathy. Clin Nutr. 2004;23(4):615–621. doi:10.1016/j.clnu.2003.10.010 PubMed DOI

Kellermann AJ, Kloft C. Is there a risk of bleeding associated with standardized Ginkgo biloba extract therapy? A systematic review and meta-analysis. Pharmacotherapy. 2011;31(5):490–502. doi:10.1592/phco.31.5.490 PubMed DOI

Luo Y, Smith JV, Paramasivam V, et al. Inhibition of amyloid-beta aggregation and caspase-3 activation by the Ginkgo biloba extract EGb761. Proc Natl Acad Sci U S A. 2002;99(19):12197–12202. doi:10.1073/pnas.182425199 PubMed DOI PMC

Tchantchou F, Xu Y, Wu Y, Christen Y, Luo Y. EGb 761 enhances adult hippocampal neurogenesis and phosphorylation of CREB in transgenic mouse model of Alzheimer’s disease. FASEB J. 2007;21(10):2400–2408. doi:10.1096/fj.06-7649com PubMed DOI

Tchantchou F, Lacor PN, Cao Z, et al. Stimulation of neurogenesis and synaptogenesis by bilobalide and quercetin via common final pathway in hippocampal neurons. J Alzheimers Dis. 2009;18(4):787–798. doi:10.3233/JAD-2009-1189 PubMed DOI

Muller WE, Eckert A, Eckert GP, et al. Therapeutic efficacy of the Ginkgo special extract EGb761 within the framework of the mitochondrial cascade hypothesis of Alzheimer’s disease. World J Biol Psychiatry. 2019;20(3):173–189. doi:10.1080/15622975.2017.1308552 PubMed DOI

Jurcău MC, Andronie-Cioara FL, Jurcău A, et al. The link between oxidative stress, mitochondrial dysfunction and neuroinflammation in the pathophysiology of Alzheimer’s disease: therapeutic implications and future perspectives. Antioxidants. 2022;11(11):2167. doi:10.3390/antiox11112167 PubMed DOI PMC

European Medicines Agency - Committee on Herbal Medicinal Products (HMPC). European Union Herbal Monograph on Ginkgo Biloba L., Folium. European Medicines Agency; 2015.

Kasper S, Bancher C, Eckert A, et al. Management of mild cognitive impairment (MCI): the need for national and international guidelines. World J Biol Psychiatry. 2020;21(8):579–594. doi:10.1080/15622975.2019.1696473 PubMed DOI

Kandiah N, Chan YF, Chen C, et al. Strategies for the use of Ginkgo biloba extract, EGb 761, in the treatment and management of mild cognitive impairment in Asia: expert consensus. CNS Neurosci Ther. 2021;27:149–162. doi:10.1111/cns.13536 PubMed DOI PMC

Hashiguchi M, Ohta Y, Shimizu M, Maruyama J, Mochizuki M. Meta-analysis of the efficacy and safety of Ginkgo biloba extract for the treatment of dementia. J Pharm Health Care Sci. 2015;1:14. doi:10.1186/s40780-015-0014-7 PubMed DOI PMC

Gauthier S, Schlaefke S. Efficacy and tolerability of Ginkgo biloba extract EGb 761 in dementia: a systematic review and meta-analysis of randomized placebo-controlled trials. Clin Interv Aging. 2014;9::2065–77. doi:10.2147/CIA.S72728 PubMed DOI PMC

Hoerr R, Zaudig M. A retrospective classification of diagnoses in terms of DSM-5 for patients included in randomized controlled trials of Ginkgo biloba extract EGb 761. Eur Arch Psychiatry Clin Neurosci. 2016;266(3):249–259. doi:10.1007/s00406-015-0632-y PubMed DOI PMC

American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders: DSM-5. American Psychiatric Association; 2013.

European Medicines Agency - Committee for Medicinal Products for Human Use (CHMP). Guideline on the Clinical Investigation of Medicines for the Treatment of Alzheimer’s Disease. European Medicines Agency; 2018.

Aisen PS, Cummings J, Doody R, et al. The future of anti-amyloid trials. J Prev Alzheimers Dis. 2020;7(3):146–151. doi:10.14283/jpad.2020.24 PubMed DOI

Budd Haeberlein S, Aisen PS, Barkhof F, et al. Two randomized phase 3 studies of aducanumab in early Alzheimer’s disease. J Prev Alzheimers Dis. 2022;9(2):197–210. doi:10.14283/jpad.2022.30 PubMed DOI

Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:n71. doi:10.1136/bmj.n71 PubMed DOI PMC

Page MJ, Moher D, Bossuyt PM, et al. PRISMA 2020 explanation and elaboration: updated guidance and exemplars for reporting systematic reviews. BMJ. 2021;372:n160. doi:10.1136/bmj.n160 PubMed DOI PMC

Jadad AR, Moore RA, Carroll D, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials. 1996;17(1):1–12. doi:10.1016/0197-2456(95)00134-4 PubMed DOI

Israel L, Dell’accio E, Martin G, Hugonot R. Extrait de Ginkgo biloba et exercices d’entrainement de la mémoire. Évaluation comparative chez des personne âgées ambulatoires. [Ginkgo biloba extract and memory training programs. Comparative assessment on elderly outpatients living in the community]. Psychol Med. 1987;19(8):1431–1439. French.

Tian J, Shi J, Wei M, et al. Chinese herbal medicine Qinggongshoutao for the treatment of amnestic mild cognitive impairment: a 52‐week randomized controlled trial. Alzheimers Dement. 2019;5(1):441–449. doi:10.1016/j.trci.2019.03.001 PubMed DOI PMC

Halama P, Bartsch G, Meng G. Hirnleistungsstörungen vaskulärer Genese. Randomisierte Doppelblindstudie zur Wirksamkeit von Gingko–biloba–Extrakt. [Disorders of brain performance of vascular origin. Randomized double-blind study of the effectiveness of Ginkgo biloba extract]. Fortschr Med. 1988;106(19):408–412. German. PubMed

Gavrilova SI, Preuss UW, Wong JW, et al. Efficacy and safety of Ginkgo biloba extract EGb 761® in mild cognitive impairment with neuropsychiatric symptoms: a randomized, placebo-controlled, double-blind, multi-center trial. Int J Geriatr Psychiatry. 2014;29(10):1087–1095. doi:10.1002/gps.4103 PubMed DOI

Grass-Kapanke B, Busmane A, Lasmanis A, Hoerr R, Kaschel R. Effects of Ginkgo biloba special extract EGb 761 in very mild cognitive impairment (vMCI). Neurosci Med. 2011;02(01):48–56. doi:10.4236/nm.2011.21007 DOI

Stocksmeier U, Eberlein M. Depressive Verstimmung bei Hirnleistungsstörungen. [Depressive mood in cerebral dysfunction. The effects of a Ginkgo biloba extract tested in a double-blind study]. TW Neurologie Psychiatrie. 1992;6:74–76. German.

Gräßel E. Einfluß von Ginkgo-biloba-Extrakt auf die geistige Leistungsfähigkeit. Doppelblindstudie unter computerisierten Meßbedingungen bei Patienten mit Zerebralinsuffizienz [The influence of Ginkgo biloba extract on mental performance. A double blind study under computerized measurement conditions in patients with cerebral insufficiency]. Fortschr Med. 1992;110(5):73–78. German. PubMed

Schubert H, Halama P. Primär therapieresistente depressive Verstimmung älterer Patienten mit Hirnleistungsstörungen: Wirksamkeit der Kombination von Ginkgo-biloba-Extrakt EGb-761 mit Antidepressiva. [Primary therapy-resistant depressive instability in elderly patients with cerebral disorders: efficacy of a combination of Ginkgo biloba extract EGb 761 with antidepressants]. Geriatrie Forschung. 1993;3(1):45–53. German.

Wesnes K, Simmons D, Rook M, Simpson P. A double-blind placebo-controlled trial of Tanakan in the treatment of idiopathic cognitive impairment in the elderly. Hum Psychopharmacol. 1987;2:159–169. doi:10.1002/hup.470020305 DOI

Wesnes K. A fully automated psychometric test battery for human psychopharmacology. Abstracts of the IVth World Congress of Biological Psychiatry, Philadelphia; 1985:153.

Lehrl S, Fischer B. The basic parameters of human information processing: their role in the determination of intelligence. Person Individ Diff. 1988;9(5):883–896. doi:10.1016/0191-8869(88)90006-2 DOI

Food and Drug Administration. U.S. Department of Health and Human Services. Alzheimer’s Disease: Developing Drugs for the Treatment of Early Stage Disease, DRAFT GUIDANCE for Industry. Food and Drug Administration; 2013.

Dieli GLM, Saetta V, Costanzo M. Studio clinico in doppio cieco del Tanakan nell’ insufficienza cerebrale cronica. [Double-blind clinical trial with Tanakan in chronic cerebral insufficiency]. Il Lavoro Neuro Psichiatrico. 1981;68(1/2):3–15. Italian.

Taillandier JA, Rabourdin JP, Ribeyre JP, Pichon J, Niddam S, Pierart H. Traitement des troubles du vieillissement cérébral par l’extrait de Ginkgo biloba. [Treatment of cerebral aging disorders with Ginkgo biloba extract]. Presse Med. 1986;15:1583–1587. French. PubMed

Hofferberth B. Einfluss von Ginkgo biloba-Extrakt auf neurophysiologische und psychometrische Messergebnisse bei Patienten mit hirnorganischem Psychosyndrom. Eine Doppelblindstdie gegen Placebo. [The effect of Ginkgo biloba extract on neurophysiological and psychometric measurement results in patients with psychotic organic brain syndrome. A double-blind study against placebo]. Arzneim-Forsch. 1989;39(8):918–922. German. PubMed

Cohen S, Cummings J, Knox S, Potashman M, Harrison J. Clinical trial endpoints and their clinical meaningfulness in early stages of Alzheimer’s disease. J Prev Alzheimers Dis. 2022;9(3):507–522. doi:10.14283/jpad.2022.41 PubMed DOI PMC

Mohs RC, Rosen WG, Davis KL. The Alzheimer’s disease assessment scale: an instrument for assessing treatment efficacy. Psychopharmacol Bull. 1983;19(3):448–450. PubMed

Reisberg B, London E, Ferris SH, Borenstein BA, Scheier L, de Leon MJ. The brief cognitive rating scale: language, motoric, and mood concomitants in primary degenerative dementia. Psychopharmacol Bull. 1983;19(4):702–708.

Mohs RC, Knopman D, Petersen RC, et al. Development of cognitive instruments for use in clinical trials of antidementia drugs: additions to the Alzheimer’s Disease Assessment Scale that broaden its scope. The Alzheimer’s Disease Cooperative Study. Alzheimer Dis Assoc Disord. 1997;11(Suppl 2):S13–S21. doi:10.1097/00002093-199700112-00003 PubMed DOI

Donohue MC, Sperling RA, Salmon DP, et al. The preclinical Alzheimer cognitive composite: measuring amyloid-related decline. JAMA Neurol. 2014;71(8):961–970. doi:10.1001/jamaneurol.2014.803 PubMed DOI PMC

Wang J, Logovinsky V, Hendrix SB, et al. ADCOMS: a composite clinical outcome for prodromal Alzheimer’s disease trials. J Neurol Neurosurg Psychiatry. 2016;87(9):993–999. doi:10.1136/jnnp-2015-312383 PubMed DOI PMC

Kaschel R. Ginkgo biloba: specificity of neuropsychological improvement – a selective review in search of differential effects. Hum Psychopharmacol. 2009;24(5):345–370. doi:10.1002/hup.1037 PubMed DOI

Sachdev PS, Lipnicki DM, Crawford JD, Brodaty H. The vascular behavioral and cognitive disorders criteria for vascular cognitive disorders: a validation study. Eur J Neurol. 2019;26(9):1161–1167. doi:10.1111/ene.13960 PubMed DOI

von Gunten A, Schlaefke S, Überla K. Efficacy of Ginkgo biloba extract EGb 761 in dementia with behavioural and psychological symptoms: a systematic review. World J Biol Psychiatry. 2016;17(8):622–633. doi:10.3109/15622975.2015.1066513 PubMed DOI

Savaskan E, Mueller H, Hoerr R, von Gunten A, Gauthier S. Treatment effects of Ginkgo biloba extract EGb 761 on the spectrum of behavioral and psychological symptoms of dementia: meta-analysis of randomized controlled trials. Int Psychogeriatr. 2018;30(3):285–293. doi:10.1017/S1041610217001892 PubMed DOI

McGirr A, Nathan S, Ghahremani M, Gill S, Smith EE, Ismail Z. Progression to dementia or reversion to normal cognition in mild cognitive impairment as a function of late-onset neuropsychiatric symptoms. Neurology. 2022;98(21):e2132–e2139. doi:10.1212/WNL.0000000000200256 PubMed DOI PMC